Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494919 | 0.91 | KDM4E (0.66) | CYP2D6CYP2C9KDM4ETDP1TSHR | |
| SCHEMBL3531517 | 0.86 | SMN1; SMN2 (0.63) | CYP2D6CYP2C9KDM4ETDP1TSHR | |
| SCHEMBL14667316 | 0.85 | HTR1A (0.53) | CYP2D6CYP2C9KDM4ETDP1HTR1A | |
| SCHEMBL3470303 | 0.85 | CYP2D6 (0.65) | CYP2D6CYP2C9KDM4ETDP1TSHR | |
| SCHEMBL23195558 | 0.84 | KDM4E (0.61) | CYP2D6CYP2C9KDM4ETDP1TSHR | |
| SCHEMBL4267324 | 0.83 | CYP2D6 (0.60) | CYP2D6CYP2C9KDM4ETDP1TSHR | |
| SCHEMBL23195583 | 0.83 | SMN1; SMN2 (0.65) | CYP2D6CYP2C9KDM4ETDP1TSHR | |
| SCHEMBL6447779 | 0.82 | SMN1; SMN2 (0.63) | CYP2D6CYP2C9KDM4ETDP1TSHR | |
| SCHEMBL20462782 | 0.81 | CYP2D6 (0.64) | CYP2D6CYP2C9KDM4ETDP1TSHR | |
| SCHEMBL11961176 | 0.81 | TSHR (0.61) | CYP2D6KDM4ETDP1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030172-A1 | Methods of Preparing Quinoline Derivatives | EXELIXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8314232-B2 | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide | GLAXOSMITHKLINE LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314232-B2 | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide | GLAXOSMITHKLINE LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010036831-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GLAXOSMITHKLINE LLC (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030172-A1 | Methods of Preparing Quinoline Derivatives | F12, RECQL, H1-2 | CYP2D6 19/4885CYP2C9 124/4885KDM4E 3851/4885 |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | QDPR, CBR3, NQO2 | CYP2D6 80/4885CYP2C9 89/4885KDM4E 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.